Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model

Fig. 3

Identification of three TIDE-based subtypes of BC based on the TIDE marker genes. A CircosPlot shows the expression levels in TCGA-BLCA, signaling pathways and protein–protein interaction (PPI) networks of 69 TIDE marker genes. These genes are mainly divided into two clusters: C1 consists of 11 genes (cyan) and C2 comprises 58 genes (red). B Consensus clustering based on the expression of 69 TIDE marker genes classified patients of TCGA-BLCA into three subtypes: Subtype I (SI), Subtype II (SII), and Subtype III (SIII). C1 genes are labelled in cyan, and C2 are labelled in red. C Levels and trends of TIDE scores among three TIDE subtypes. D OS of TCGA-BLCA is significantly different among three TIDE subtypes. E, F Univariate (E) and multivariate (F) Cox regression analysis of the three TIDE subtypes with clinical and molecular characteristics. *p < 0.05, ***p < 0.001, ****p < 0.0001

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us